trending Market Intelligence /marketintelligence/en/news-insights/trending/bs3bpupkfwmnt4gjqaqg2w2 content esgSubNav
In This List

Tenax Therapeutics names CEO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Tenax Therapeutics names CEO

Tenax Therapeutics Inc. appointed Anthony DiTonno CEO, effective June 1.

Michael Jebsen, the company's current interim CEO and CFO, will continue to serve as CFO after DiTonno's appointment.

DiTonno has been a director of Tenax since December 2011. He served as CEO of Avantis Medical Systems Inc., a medical device company that develops and manufactures catheter-based endoscopic devices, from January 2013 until May 31, 2018.

Morrisville, N.C.-based Tenax Therapeutics is a specialty pharmaceutical company, which focuses on the identification, development and commercialization of a portfolio of products for the critical care market.